These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 22339855)

  • 41. Functional characterization of the mucus barrier on the
    Dubaissi E; Rousseau K; Hughes GW; Ridley C; Grencis RK; Roberts IS; Thornton DJ
    Proc Natl Acad Sci U S A; 2018 Jan; 115(4):726-731. PubMed ID: 29311327
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Beyond PEGylation: Alternative surface-modification of nanoparticles with mucus-inert biomaterials.
    Khutoryanskiy VV
    Adv Drug Deliv Rev; 2018 Jan; 124():140-149. PubMed ID: 28736302
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Functionalized positive nanoparticles reduce mucin swelling and dispersion.
    Chen EY; Wang YC; Chen CS; Chin WC
    PLoS One; 2010 Nov; 5(11):e15434. PubMed ID: 21085670
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mucins: a biologically relevant glycan barrier in mucosal protection.
    Corfield AP
    Biochim Biophys Acta; 2015 Jan; 1850(1):236-52. PubMed ID: 24821013
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Modeling Barrier Properties of Intestinal Mucus Reinforced with IgG and Secretory IgA against Motile Bacteria.
    Xu F; Newby JM; Schiller JL; Schroeder HA; Wessler T; Chen A; Forest MG; Lai SK
    ACS Infect Dis; 2019 Sep; 5(9):1570-1580. PubMed ID: 31268295
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fast renewal of the distal colonic mucus layers by the surface goblet cells as measured by in vivo labeling of mucin glycoproteins.
    Johansson ME
    PLoS One; 2012; 7(7):e41009. PubMed ID: 22815896
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Disruption of the mucus barrier by topically applied exogenous particles.
    McGill SL; Smyth HD
    Mol Pharm; 2010 Dec; 7(6):2280-8. PubMed ID: 20919744
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Proteomic analyses of the two mucus layers of the colon barrier reveal that their main component, the Muc2 mucin, is strongly bound to the Fcgbp protein.
    Johansson ME; Thomsson KA; Hansson GC
    J Proteome Res; 2009 Jul; 8(7):3549-57. PubMed ID: 19432394
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A free-floating mucin layer to investigate the effect of the local microenvironment in lungs on mucin-nanoparticle interactions.
    Wan F; Herzberg M; Huang Z; Hassenkam T; Nielsen HM
    Acta Biomater; 2020 Mar; 104():115-123. PubMed ID: 31945503
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-PEG antibodies alter the mobility and biodistribution of densely PEGylated nanoparticles in mucus.
    Henry CE; Wang YY; Yang Q; Hoang T; Chattopadhyay S; Hoen T; Ensign LM; Nunn KL; Schroeder H; McCallen J; Moench T; Cone R; Roffler SR; Lai SK
    Acta Biomater; 2016 Oct; 43():61-70. PubMed ID: 27424083
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CFTR, mucins, and mucus obstruction in cystic fibrosis.
    Kreda SM; Davis CW; Rose MC
    Cold Spring Harb Perspect Med; 2012 Sep; 2(9):a009589. PubMed ID: 22951447
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mucin Biopolymers and Their Barrier Function at Airway Surfaces.
    Song D; Cahn D; Duncan GA
    Langmuir; 2020 Nov; 36(43):12773-12783. PubMed ID: 33094612
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of lattice constraints in coarse-grained protein models.
    Farris ACK; Seaton DT; Landau DP
    J Chem Phys; 2021 Feb; 154(8):084903. PubMed ID: 33639740
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The structure of secreted mucins isolated from the adherent mucus gel: comparison with the gene products.
    Fogg FJ; Allen A; Harding SE; Pearson JP
    Biochem Soc Trans; 1994 May; 22(2):229S. PubMed ID: 7958291
    [No Abstract]   [Full Text] [Related]  

  • 55. Bifidobacterium dentium Fortifies the Intestinal Mucus Layer via Autophagy and Calcium Signaling Pathways.
    Engevik MA; Luk B; Chang-Graham AL; Hall A; Herrmann B; Ruan W; Endres BT; Shi Z; Garey KW; Hyser JM; Versalovic J
    mBio; 2019 Jun; 10(3):. PubMed ID: 31213556
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Trefoil Factor Family (TFF) Modules Are Characteristic Constituents of Separate Mucin Complexes in the
    Stürmer R; Reising J; Hoffmann W
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244312
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A New Class of Safe Oligosaccharide Polymer Therapy To Modify the Mucus Barrier of Chronic Respiratory Disease.
    Pritchard MF; Powell LC; Menzies GE; Lewis PD; Hawkins K; Wright C; Doull I; Walsh TR; Onsøyen E; Dessen A; Myrvold R; Rye PD; Myrset AH; Stevens HN; Hodges LA; MacGregor G; Neilly JB; Hill KE; Thomas DW
    Mol Pharm; 2016 Mar; 13(3):863-72. PubMed ID: 26833139
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mucoadhesion vs mucus permeability of thiolated chitosan polymers and their resulting nanoparticles using a quartz crystal microbalance with dissipation (QCM-D).
    Oh S; Borrós S
    Colloids Surf B Biointerfaces; 2016 Nov; 147():434-441. PubMed ID: 27568354
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Technological strategies to estimate and control diffusive passage times through the mucus barrier in mucosal drug delivery.
    Newby JM; Seim I; Lysy M; Ling Y; Huckaby J; Lai SK; Forest MG
    Adv Drug Deliv Rev; 2018 Jan; 124():64-81. PubMed ID: 29246855
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Probing the interaction of nanoparticles with mucin for drug delivery applications using dynamic light scattering.
    Griffiths PC; Cattoz B; Ibrahim MS; Anuonye JC
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):218-22. PubMed ID: 25986588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.